These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

990 related items for PubMed ID: 29473704

  • 1. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J.
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [Abstract] [Full Text] [Related]

  • 2. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z.
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [Abstract] [Full Text] [Related]

  • 3. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C.
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH, Rosenstock J, Vetter ML, Dong F, Öhman P, Iqbal N.
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W, Min K, Zhou Z, Li L, Xu X, Zhu D, Venkateshwar Rao A, Murthy LS, Zhang N, Li I, Niemoeller E, Shang S.
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [Abstract] [Full Text] [Related]

  • 6. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM, Weitgasser R, Perez Manghi F, Pintilei E, Fahrbach JL, Jiang HH, Shell J, Robertson KE.
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
    Jabbour SA, Frías JP, Ahmed A, Hardy E, Choi J, Sjöström CD, Guja C.
    Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
    [Abstract] [Full Text] [Related]

  • 8. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y, Senda M, Naito Y, Tamura M, Watanabe D, Shuto Y, Urita Y.
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T.
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
    Unni S, Wittbrodt E, Ma J, Schauerhamer M, Hurd J, Ruiz-Negrón N, McAdam-Marx C.
    Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH, 4B Study Group.
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
    Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, DURATION-NEO-2 study investigators.
    Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
    [Abstract] [Full Text] [Related]

  • 13. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J, Xiao W, Guo L, Li Q, Zhong L, Yang J, Yang J, Gao Y, Tian Q, Hong T.
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.
    Lancet; 2018 Nov 17; 392(10160):2180-2193. PubMed ID: 30293770
    [Abstract] [Full Text] [Related]

  • 16. Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
    Guerci B, Trautmann ME, Lin T, Hardy E, Mudaliar SRD.
    Diabetes Obes Metab; 2019 Apr 17; 21(4):1049-1053. PubMed ID: 30520252
    [Abstract] [Full Text] [Related]

  • 17. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M, Van Gaal L, Guerci B, Stranks S, Han J, Malloy J, Boardman MK, Trautmann ME.
    Lancet Diabetes Endocrinol; 2014 Jun 17; 2(6):464-73. PubMed ID: 24731672
    [Abstract] [Full Text] [Related]

  • 18. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
    Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J.
    Diabetes Obes Metab; 2017 Dec 17; 19(12):1798-1804. PubMed ID: 28432746
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ.
    Diabetes Obes Metab; 2017 Apr 17; 19(4):524-536. PubMed ID: 27981757
    [Abstract] [Full Text] [Related]

  • 20. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
    Shaw JE, Gallwitz B, Han J, Hardy E, Schernthaner G.
    Diabetes Obes Metab; 2017 Dec 17; 19(12):1793-1797. PubMed ID: 28573708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.